$8.13
2.17% today
Nasdaq, Apr 25, 05:49 pm CET
ISIN
US88025U1097
Symbol
TXG
Sector
Industry

10x Genomics Inc - Ordinary Shares - Class A Stock price

$8.31
-2.08 20.02% 1M
-7.16 46.28% 6M
-6.05 42.13% YTD
-19.21 69.80% 1Y
-46.74 84.90% 3Y
-65.69 88.77% 5Y
-44.44 84.25% 10Y
Nasdaq, Closing price Thu, Apr 24 2025
+0.30 3.68%
ISIN
US88025U1097
Symbol
TXG
Sector
Industry

Key metrics

Market capitalization $1.02b
Enterprise Value $712.45m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.17
P/S ratio (TTM) P/S ratio 1.68
P/B ratio (TTM) P/B ratio 1.43
Revenue growth (TTM) Revenue growth -1.28%
Revenue (TTM) Revenue $610.79m
EBIT (operating result TTM) EBIT $-192.20m
Free Cash Flow (TTM) Free Cash Flow $-5.73m
Cash position $393.40m
EPS (TTM) EPS $-1.52
P/E forward negative
P/S forward 1.68
EV/Sales forward 1.17
Short interest 12.87%
Show more

Is 10x Genomics Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

10x Genomics Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a 10x Genomics Inc - Ordinary Shares - Class A forecast:

8x Buy
40%
10x Hold
50%
2x Sell
10%

Analyst Opinions

20 Analysts have issued a 10x Genomics Inc - Ordinary Shares - Class A forecast:

Buy
40%
Hold
50%
Sell
10%

Financial data from 10x Genomics Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
611 611
1% 1%
100%
- Direct Costs 183 183
25% 25%
30%
428 428
15% 15%
70%
- Selling and Administrative Expenses 313 313
4% 4%
51%
- Research and Development Expense 264 264
12% 12%
43%
-148 -148
8% 8%
-24%
- Depreciation and Amortization 44 44
0% 0%
7%
EBIT (Operating Income) EBIT -192 -192
6% 6%
-31%
Net Profit -183 -183
28% 28%
-30%

In millions USD.

Don't miss a Thing! We will send you all news about 10x Genomics Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

10x Genomics Inc - Ordinary Shares - Class A Stock News

Neutral
Business Wire
22 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #neuroscience--Vizgen, Inc., the life sciences company revolutionizing spatial genomics research and driving innovation in spatial multi-omics, today released an open letter in response to the settlement of litigation between Vizgen, Harvard University and 10X Genomics in the United States District Court for the District of Delaware. Dear Customers, Researche...
Positive
Seeking Alpha
about one month ago
I assign TXG a buy rating with a 1-year price target of $12.7 per share, projecting an 18% upside YoY. TXG's new lower-cost Chromium offerings could drive volume growth and increased adoption, particularly in the biopharma sector, presenting significant revenue opportunities. Despite historical underperformance and high risk, TXG's leading technologies and potential market penetration justify h...
Neutral
PRNewsWire
about 2 months ago
10x Genomics' ATAC-Seq patents found valid and infringed PLEASANTON, Calif. , March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.
More 10x Genomics Inc - Ordinary Shares - Class A News

Company Profile

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company's products include Single Cell Gene Expression, Immune Profiling, CNV, ATAC, and Genome and Exome. 10X Genomics was founded by Serge Saxonov, Ben Hindson, Kevin D. Ness and Eduard Diviu Terradas on July 2, 2012 and is headquartered in Pleasanton, CA.

Head office United States
CEO Serge Saxonov
Employees 1,306
Founded 2012
Website www.10xgenomics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today